Search

By Industry Solutions (2)
By Phase (1)
By Molecule Type (1)
By Therapeutic Area (3)
Covance Events (9)
Geography (3)
Keywords (10)

Filters

Showing results 1217 - 1232 of 91813 for .

Showing results 1217 - 1232 of 91813 for .

Dallas - Covance Clinical Research Unit
Site features for Covance Clinical Research Unit in Dallas, TX
Daytona Beach - Covance Clinical Research Unit
Site features for Covance Clinical Research Unit in Daytona Beach, FL
Indiana CTSI - Covance Clinical Research Center
Site features for Covance Clinical Research Center at Indiana CTSI, Indianapolis, IN
Leeds - Covance Clinical Research Unit
Site features for Covance Clinical Research Unit in Leeds, England
Covance & Royal Liverpool University Hospital - Covance Clinical Research Unit
Site features for Covance Clinical Research Unit at Royal Liverpool University Hospital
Madison - Covance Clinical Research Unit
Site features for Covance Clinical Research Unit in Madison, WI
CRU Visitor Guide - Dallas, Texas
Information for visitors to the Covance Clinical Research Unit in Dallas, TX
CRU Visitor Guide - Daytona Beach, Florida
Information for visitors to the Covance Clinical Research Unit in Daytona Beach, FL
CRU Visitor Guide - Leeds, United Kingdom
Information for visitors to the Covance Clinical Research Unit in Leeds, UK
CRU Visitor Guide - Madison, Wisconsin
Information for visitors to the Covance Clinical Research Unit in Madison, WI
FIVE SOLUTIONS FOR ADDRESSING ANTIBIOTIC DEVELOPMENT CHALLENGES
Each year, 2 million people in the U.S. are infected with multidrug-resistant bacteria and at least 23,000 of those die as a direct result of these infections . Similarly, in the European Union (EU), about 25,000 people die from these infections while the World Health Organization (WHO) has observed very high rates of resistance in its regions , signaling a worldwide threat to global health with devastating implications. The crisis is only compounded by limited antibiotic development in...
SIX SOLUTIONS FOR ADDRESSING ANTIBIOTIC DEVELOPMENT CHALLENGES
Each year, 2 million people in the U.S. are infected with multidrug-resistant bacteria and at least 23,000 of those die as a direct result of these infections . Similarly, in the European Union (EU), about 25,000 people die from these infections while the World Health Organization (WHO) has observed very high rates of resistance in its regions , signaling a worldwide threat to global health with devastating implications. The crisis is only compounded by limited antibiotic development in...
Adaptive Trial Designs: Improving the Efficiency of Drug Development
The productivity rate of drug development continues to fall, with clinical trial efficiency a driving factor. Learn more about how adaptive clinical trials can improve both predictability and efficiency.
Arsenic and Lead Lessons Learned
Deliberations about unsafe levels of arsenic in products such as juice and rice have troubled the food industry in recent years. At the scientific heart of the controversy was The Joint FAO/WHO Expert Committee on Food Additives (JECFA) and the European Food Safety Authority (EFSA) determination in 2009 and 2010 that existing maximum allowable limits were not protecting public health-and that they lacked sufficient information to establish new maximums.
Assessment of Abuse Liability of Brain-Penetrant Compounds: Regulatory Environment, Challenges and Opportunities in View of the Current Opioid Epidemic
Abuse liability of a drug refers to its potential use in a non-medical situation for the positive psychoactive effects it produces through its Central Nervous System (CNS) activity. The assessment of the abuse liability/potential of a drug encompasses all properties of the drug (chemical, pharmacological, pharmacokinetics, usage and diversion history), and is part of the overall assessment of drug safety under the evaluation of a New Drug Application (NDA) in the U.S. or a Market...